(BDX) Becton Dickinson - Ratings and Ratios

Becton, Dickinson and Company (NYSE:BDX) is a global medical technology firm specializing in the development, production, and distribution of medical supplies, devices, laboratory equipment, and diagnostic systems. The company serves a diverse range of customers, including healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical companies, and the general public. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BDX operates through three primary business segments: BD Medical, BD Life Sciences, and BD Interventional.

The BD Medical segment offers a wide array of products, including peripheral IV catheters, central lines, vascular access technologies, needle-free IV connectors, closed-system drug transfer devices, hypodermic syringes, and sharps disposal systems. It also provides medication safety and infusion therapy systems, automated dispensing systems, and hemodynamic monitoring solutions. Additionally, the segment includes prefillable drug delivery systems, which are critical for pharmaceutical companies.

The BD Life Sciences segment focuses on diagnostic and research solutions, offering blood and specimen collection products, automated culturing systems for blood and tuberculosis, molecular testing platforms, and fluorescence-activated cell sorters and analyzers. It also provides reagents and kits for single-cell gene expression analysis, as well as diagnostic/monitoring tools for oncology, immunology, and transplantation.

The BD Interventional segment specializes in surgical and interventional products, including hernia repair systems, biosurgery solutions, peripheral intervention devices, and urology products. This segment also offers surgical infection prevention solutions and critical care products, addressing a broad spectrum of clinical needs.

As of the latest data, BDX has a market capitalization of $57.42 billion, with a trailing P/E ratio of 33.45 and a forward P/E of 14.29. The stock is trading at $198.71, below its 20-day SMA of $215.26 and 50-day SMA of $222.03. The average true range (ATR) is 6.17, indicating moderate price volatility.

3-Month Forecast: Based on the current technical and fundamental data, BDX is expected to trade in a range of $190-$210 over the next three months. The stock is likely to face resistance at its 50-day SMA of $222.03 and support at $190, given its recent price action and volatility metrics. The forward P/E of 14.29 suggests potential upside as earnings growth aligns with market expectations.